Quoin Pharmaceuticals (Quoin Pharmaceuticals) EBIT per Share : $-7.49 (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Quoin Pharmaceuticals EBIT per Share?

Quoin Pharmaceuticals's EBIT per Share for the three months ended in Mar. 2024 was $-1.17. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-7.49.

During the past 3 years, the average EBIT per Share Growth Rate was 29.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Quoin Pharmaceuticals's EBIT per Share or its related term are showing as below:

QNRX' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -18.1 Med: 5.75 Max: 29.6
Current: 29.6

During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Quoin Pharmaceuticals was 29.60% per year. The lowest was -18.10% per year. And the median was 5.75% per year.

QNRX's 3-Year EBIT Growth Rate is ranked better than
80.55% of 1301 companies
in the Biotechnology industry
Industry Median: 3.4 vs QNRX: 29.60

Quoin Pharmaceuticals's EBIT for the three months ended in Mar. 2024 was $-2.46 Mil.

Quoin Pharmaceuticals EBIT per Share Historical Data

The historical data trend for Quoin Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quoin Pharmaceuticals EBIT per Share Chart

Quoin Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

-27.86

-36.57

-783.54

-42.91

-9.64

Quoin Pharmaceuticals Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial												-4.36	-2.29	-1.95	-2.08	-1.17

Quoin Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Quoin Pharmaceuticals's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-8.687	/	0.901
=	-9.64

Quoin Pharmaceuticals's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2.458	/	2.103
=	-1.17

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.49

Quoin Pharmaceuticals (NAS:QNRX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Quoin Pharmaceuticals EBIT per Share Related Terms

Thank you for viewing the detailed overview of Quoin Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Quoin Pharmaceuticals (Quoin Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Quoin Pharmaceuticals Ltd (NAS:QNRX) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

42127 Pleasant Forest Court, Ashburn, VA, USA, 20148-7349

Website

https://www.quoinpharma.com

Quoin Pharmaceuticals Ltd is a pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.

Executives

Dennis Langer	director	C/O PETER TSOFLIAS, BLANK ROME LLP, ONE LOGAN SQUARE, FL 9, PHILADELPHA PA 19103
Michael T Sember	director	AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 671101
Joseph Patrick Cooper	director	PETER TSOFLIAS, C/O BLANK ROME LLP, ONE LOGAN SQUARE, FL 9, PHILADELPHIA PA 19103
Anthony James Culverwell	director	C/O QUOIN PHARMACEUTICALS, LTD., AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 6701101
Gordon Dunn	officer: Chief Financial Officer	AZRIELI CENTER, ROUND TOWER, TER AVIV L3 6701101
Denise P. Carter	director, officer: Chief Operating Officer	AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 9701101
Leong Natalie Ee Mun	director	AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 6701101
Michael Myers	director, officer: Chief Executive Officer	AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 6701101